Aquinox Pharmaceuticals Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Leerink Maintains Aquinox Pharma (AQXP) at 'Outperform'; End-of-Phase 2 FDA Meeting is Next Catalyst
November 10, 2015 2:18 PM ESTLeerink affirms Aquinox Pharma (Nasdaq: AQXP) with an Outperform rating and $26 price target following the company's Q3 results and update... More
Aquinox Pharma (AQXP) Posts Narrower-than-Expected Q3 Loss
November 10, 2015 9:20 AM ESTAquinox Pharma (NASDAQ: AQXP) reported Q3 EPS of ($0.43), $0.02 better than the analyst estimate of ($0.45).
With positive results from the LEADERSHIP trial, we are advancing towards pivotal trials in bladder pain syndrome/interstitial cystitis (BPS/IC) with AQX-1125, said Mr. David Main, President and... More
